Aadi Bioscience (FRA:3350) Common Stock : €0.00 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Aadi Bioscience Common Stock?

Aadi Bioscience's quarterly common stock stayed the same from Sep. 2023 (€0.00 Mil) to Dec. 2023 (€0.00 Mil) and stayed the same from Dec. 2023 (€0.00 Mil) to Mar. 2024 (€0.00 Mil).

Aadi Bioscience's annual common stock stayed the same from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€0.00 Mil) and stayed the same from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€0.00 Mil).

Aadi Bioscience Common Stock Historical Data

The historical data trend for Aadi Bioscience's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aadi Bioscience Common Stock Chart

Aadi Bioscience Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Common Stock

Aadi Bioscience Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Common Stock	Get a 7-Day Free Trial										-	-	-	-	-

Aadi Bioscience Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Aadi Bioscience (FRA:3350) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aadi Bioscience Inc (FRA:3350) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

AADI:USA 3350:Germany

Address

17383 Sunset Boulevard, Suite A250, Pacific Palisades, CA, USA, 90272

Website

https://www.aadibio.com

Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.

Aadi Bioscience (FRA:3350) Headlines

No Headlines